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Abstract 
Chronic obstructive pulmonary disease (COPD) is a problem whose urgency is growing rapidly around 
the world. The main risk factor for COPD development is smoking. Epidemiological studies, conducted 
in most countries of the world, found a significant increase in the number of patients among tobacco 
smokers. According to WHO, there are more than 1.1 billion of smokers all over the world, and it is the 
most common bad habit that leads to the occurrence of COPD. 
Aim: Тo study the impact of smoking on the condition of proteinase-inhibitory system in patients with 
COPD. 
Materials and methods: The study involved 164 men with COPD aged from 36 to 59 years, with 
disease duration from 9.2 to 15.3 years. Depending on the clinical and functional characteristics of the 
disease, the severity degree, as well as taking into account active smoking. To assess the nature and 
prevalence of chronic inflammation in COPD patients, fiber-optic bronchoscopy (FBS) was conducted. 
To determine nicotine dependence in smokers, the questionnaire by K.O. Fagerstrom was used. Study of 
the activity of protease-inhibitory enzymes in bronchoalveolar fluid was conducted with conversion of 
enzyme activity in total amount of proteins by Lowry method. 
Results: In bronchoalveolar fluid of patients with COPD, the imbalance in the protease-inhibitory system 
was revealed with predominance of proteinase potential: in smokers, the activity of TR group increases 
as compared with the group of healthy individuals and non-smokers with COPD. It has been found that 
the imbalance in protease-inhibitory system in patients progresses depending on the index “pack-years” 
of smoking. High rates of α2MH in bronchoalveolar fluid at increased inflammatory activity indicate that 
in the depletion α1AT, the present inhibitor can perform basic protection functions. It has been revealed 
that the most informative indicator in assessing the state of proteinase-inhibitory system in patients with 
COPD is the ratio of trypsin/α1antitrypsin. 
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1. Introduction 
Chronic obstructive pulmonary disease (COPD) is a problem whose urgency is growing 
rapidly around the world. Despite the advances in prevention and development of therapeutic 
intervention, COPD is the most common disease in the world and the leader by the frequency 
of complications. 
According to WHO, this pathology occupies the 4th place among the leading causes of death. 
In Ukraine, the prevalence of COPD and bronchial asthma (BA) is very high, which affects the 
overall health of the nation as a whole and involves significant economic losses. In this regard, 
much research is devoted to further study of the issue [1]. 
The main risk factor for COPD development is smoking. Epidemiological studies, conducted 
in most countries of the world, found a significant increase in the number of patients among 
tobacco smokers. According to WHO, there are more than 1.1 billion of smokers all over the 
world, and it is the most common bad habit that leads to the occurrence of COPD. 
According to the scientific literature, the development of lung disease in smokers results in the 
rapid formation of respiratory failure, emphysema and disability. Tobacco smoke is a trigger 
factor in the development of chronic inflammation in COPD, the manifestation degree of 
whose pathogenic effect depends on the inadequacy of protective systems of the body. One of 
the major systems of the body which control homeostasis is proteinase-inhibitory system, 
changes in which give rise to the development of diseases [3]. However, few research works 
have been devoted to study of the features of chronic lung disease in smokers; the prophylactic 
guidelines for this category of patients have not been developed. 
In this regard, the study of the impact of smoking on the condition of biochemical processes in 
the lung tissue, particularly on the state of proteinase-inhibitory system, will further clarify the 
pathogenesis of COPD. 
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The aim of the research is to study the impact of smoking on 
the condition of proteinase-inhibitory system in patients with 
COPD. 
 
2. Materials and methods of the research 
The study involved 164 men with COPD aged from 36 to 59 
years (average age – 52.1 ± 2.4 years) with disease duration 
from 9.2 to 15.3 years (on average – 11.5 ± 1.2 years). 
Depending on the clinical and functional characteristics of the 
disease, the severity degree, as well as taking into account 
active smoking, the following clinical groups were 
distinguished: 
The 1st group included 84 patients with COPD [2]. Duration of 
smoking: from 20 to 35 years (on average 30.4 ± 1.8 years) 
and a high degree of nicotine dependence according to 
questionnaire by K.O. Fagerstrom. 
Subgroup 1A − 28 patients with bronchial obstruction of 1 
degree, clinical group A, acute stage, pulmonary insufficiency 
of 0 degree. 
Subgroup 1B − 56 patients with bronchial obstruction of 3 
degree, clinical group C, acute stage, pulmonary insufficiency 
of 2 degree. 
The 2nd group included 80 patients with COPD who had 
never smoked. 
Subgroup 2A − 32 patients with bronchial obstruction of 1 
degree, clinical group A, acute stage, pulmonary insufficiency 
of 0 degree. 
Subgroup 2B − 48 patients with bronchial obstruction of 3 
degree, clinical group C, acute stage, pulmonary insufficiency 
of 2 degree. 
The 3rd − control group, − included 32 men who had never 
smoked and as a result of clinical and laboratory studies have 
been diagnosed as apparently healthy. 
To assess the nature and prevalence of chronic inflammation 
in COPD patients, fiber-optic bronchoscopy (FBS) was 
conducted. 
To determine nicotine dependence in smokers, the 
questionnaire by K.O. Fagerstrom was used. Active habit of 
smoking was calculated in units of “pack-years”. Patients 
with COPD of group 1 had a high degree of nicotine 
dependence according to the questionnaire by K.O. 
Fagerstrom, the total number of “pack-years” of smoking 
ranged from 5 to 30 (on average – 25.5 ± 1.2 “pack-years” of 
smoking). 
The method to determine the activity of proteinase enzymes − 
trypsin, α1antitrypsin (α1AT), α2macroglobulin (α2MG) was 
based on the technique “Method for biochemical diagnostics 
of lung condition in bronchopulmonary diseases” [6]. 
Study of the activity of protease-inhibitory enzymes in 
bronchoalveolar fluid was conducted with conversion of 
enzyme activity in total amount of proteins by Lowry method [7]. 
Statistical analysis of the results was carried out on a personal 
computer using the "Microsoft Excel 97" software and the 
application package Statistica (license number 50083-005-
4638086-02896) by conventional methods of variation 
statistics using Student's test and correlation analysis [4]. 
 
3. Results and Discussion 
In bronchoalveolar fluid of patients with COPD, imbalance in 
the protease-inhibitor system was detected with predominance 
of proteinase potential. In the mild course of the disease in 
smokers, the level of TR activity increased by 3.2 times as 
compared with a group of healthy individuals, and by 1.6 
times as compared with patients with COPD who do not 
smoke. With increased activity of trypsin (TR), the levels of 
protease inhibitors α1antitrypsin (α1AT) and 
α2macroglobulin (α2MG) significantly increase. Activity of 
α1AT in smokers increases by 1.7 times, α2MH – by 1.2 
times as compared with the control group. In patients who do 
not smoke, the activity α1AT α2MH does not dramatically 
change. The most significant changes in the state of 
proteinase-inhibitory system were observed in the moderate 
course of COPD. In smokers, TR activity was increased by 
4.5 times as compared with the group of healthy individuals 
and by 1.2 times as compared with non-smokers with COPD. 
In response to the increased activity of TR, the parameters of 
proteinase inhibitor activity significantly increased, activity 
α1AT increased by 1.9 times, α2MH − by 1.5 times as 
compared to control indicators (p<0.05) (see Table 1). 
Analyzing the data, one can conclude that with the 
progression of the disease and increased severity degree, the 
activity of protease-inhibitory enzymes also increases and the 
imbalance between the protease potential and inhibitors 
activity appears. 
 
Table 1: Parameters of activity of protease-inhibitory enzymes in bronchoalveolar fluid, depending on the severity of COPD 
 
 Subgroups of patients 1А 1B 2А 2B 3 
Trypsin nmol/(c.l) 1.50±0.20* 2.10±0.10*■˜ 0.91±0.11* 1.72±0.20* 0.47±0.10 
α1 anti-trypsin ncm/(c.l.) 1.44±0.10* 1.61±0.20*■˜ 0.88±0.09* 1.39±0.01* 0.84±0.02 
α2 macroglobulin ncm/(c.l.) 0.015±0.001* 0.017±0.012*■ 0.012±0.001* 0.014±0.001* 0.008±0.001 
Notes: 
1. *p<0.05 reliability of difference in the comparison with control indicators. 
2. ~p<0.05 reliability of difference in the comparison of 1A-1B subgroups. 
3. ■ p<0.05 reliability of difference in the comparison of 2A-2B subgroups. 
 
In the study, we were interested in the previous diseases, 
which could provoke COPD. Important role in this regard 
belongs to acute bronchitis in the first place, and then chronic 
bronchitis, accompanied by cough syndrome, which is the 
background that gives rise to COPD in adulthood. Collecting 
the anamnesis, it has been revealed that in 69% of patients, 
previous cases of recurrent influenza were noted; 5% of cases 
suffered from tuberculosis in the childhood. Therefore, the 
onset of COPD against the background of frequent colds can 
be characterized as oligosymptomatic, undistinguished, but in 
adulthood it is manifested by progressive shortness of breath, 
changes in spirogram, and leads to the formation of 
irreversible changes in lung tissue. 
The study found that the imbalance in the protease-inhibitory 
system in patients progresses according to the index of “pack-
years” of smoking. High rates of α2MH in bronchoalveolar 
fluid at increased inflammatory activity indicate that in the 
depletion of α1AT, the present inhibitor can perform basic 
protection functions. 
A direct highly probable correlation between the activity of 
TR and α1AT (r=0.72) has been found. Given the identified 
dependence, the ratio TR/α1AT was calculated. Based on the 
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analysis of clinical features of the disease, function 
parameters of external respiratory, values of activity of α1AT, 
TR and α2MH, as well as the TR/α1AT coefficient, it has 
been found that the value of TP/α1AT is of significant 
informational capacity and has a high probability regarding 
the course of the disease. The maximum values of TP/α1AT 
are registered in smokers with COPD of medium severe form; 
the minimum values were found in non-smokers with mild 
COPD. 
In patients with an index up to 10 "pack-years" of smoking, 
the minimal changes in the activity of protease-inhibitory 
enzymes in bronchoalveolar fluid were revealed; the rate 
TR/α1AT in these patients ranged from 0.65 to 0.83. In 
patients with an index from 11 to 20 “pack-years” of 
smoking, a moderate imbalance in protease-inhibitory system 
was found; the ratio TR/α1AT in these patients ranged from 
0.83 to 1.25. In patients with an index of "pack-years" 20 or 
above, the maximum protease activity of TR was detected 
against the background of a sharp decline in the activity of 
α1AT; these patients had the rate TR/α1AT of more than 1.25. 
Thus, the present study found that tobacco smokers, suffering 
from COPD, are characterized by the formation of higher 
levels of proteases, which leads to the imbalance in protease-
inhibitory system and can lead to the destruction of lung 
tissue. 
 
4. Conclusions 
1. In bronchoalveolar fluid of patients with COPD, the 
imbalance in the protease-inhibitory system was revealed 
with predominance of proteinase potential: in smokers, 
the activity of TR group increases as compared with the 
group of healthy individuals and non-smokers with 
COPD.  
2. It has been found that the imbalance in protease-
inhibitory system in patients progresses depending on the 
index “pack-years” of smoking.  
3. High rates of α2MH in bronchoalveolar fluid at increased 
inflammatory activity indicate that in the depletion α1AT, 
the present inhibitor can perform basic protection 
functions.  
4. It has been revealed that the most informative indicator in 
assessing the state of proteinase-inhibitory system in 
patients with COPD is the ratio of trypsin/α1antitrypsin. 
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